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Abstract
Statins are competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reduc-
tase, a rate-limiting enzyme in cholesterol synthesis. Statins are widely used in the 
treatment of hypercholesterolemia and to reduce risk of acute cardiovascular and cere-
brovascular events. Statins inhibit synthesis of not only cholesterol but also of non-
steroid isoprenoids such as farnesyl- and geranylgeranylpyrophosphate, coenzyme Q 
(ubiquinone), dolichol, etc., which are involved in multiple cell metabolic and signaling 
cascades. Adipose tissue may be an important target for statins. Although statins have 
no effect on body weight and energy balance, they inhibit differentiation of preadipo-
cytes to mature adipocytes and may induce adipocyte apoptosis. Stimulation of lipo-
protein lipase in adipose tissue accelerates VLDL metabolism and may contribute to 
triglyceride-lowering effect of statins. According to some studies, statins reduce insulin 
sensitivity of adipose tissue and impair glucose metabolism in adipocytes. Statins also 
inhibit adipose tissue inflammation which plays an important role in obesity-associat-
ed pathologies. Finally, statins modulate production of adipokines such as leptin, adi-
ponectin, resistin and visfatin. Currently available data suggest that effects on adipose 
tissue contribute to both beneficial and adverse consequences of statin therapy.
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Introduction
Stat��s are �ompet�t�ve ������tors of 
3��ydroxy�3�met�yl�l�taryl�oe��
zyme A (�M��CoA) red��tase, a 
rate l�m�t��� e�zyme �� ��olesterol 
��osy�t�es�s, ����� �o�verts �M��
CoA to mevalo�ate (F��. 1). C�rre�tly 
ava�la�le stat��s may �e �lass�fied ��to 
t�o �ro�ps. �at�ral stat��s ���l�de 
lovastat��, ����� �s a f���al meta�o�
l�te, a�d �ts sy�t�et�� der�vat�ves, prav�
astat�� a�d s�mvastat��. Fl�vastat��, 
atorvastat�� a�d ros�vastat�� are f�lly 
sy�t�et�� �ompo��ds ��t� �ompletely 
d�ffere�t ��em��al str��t�re. A�ot��
er sy�t�et�� stat��, �er�vastat��, �as 
��t�dra�� from t�e market �� 2001 
d�e to ma�y reported �ases of fatal 
r�a�domyolys�s. A �e� sy�t�et�� sta�
t��, p�tavastat��, �as ��trod��ed �� 
2003, �o�ever, ��t�l �o� �s ava�la�le 
o�ly �� Japa� a�d ��d�a.
 Stat��s de�rease plasma lo��de��
s�ty l�poprote�� (LDL) ��olesterol �y 
��d����� ��tra�ell�lar ��olesterol de�
plet�o� a�d �pre��lat��� �epat�� LDL 
re�eptors. �� add�t�o�, stat��s mod�
erately ���rease �DL���olesterol a�d 
red��e plasma tr��ly�er�des. Ma�y 
�l����al tr�als �ave demo�strated t�at 
stat��s effe�t�vely preve�t a��te �ard��
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ovas��lar eve�ts a�d red��e mortal�ty �� pr�mary a�d se�o�dary 
preve�t�o� of �s��em�� �eart d�sease (1,2). ���t�ally ��trod��ed 
as ��olesterol�lo�er��� dr��s, stat��s posses m�lt�ple ot�er l�p�
�d���depe�de�t or “ple�otrop��” at�eroprote�t�ve a�t�v�t�es s��� 
as �mproveme�t of e�dot�el�al f���t�o�, ������t�o� of ��flamma�
tory rea�t�o�, platelet a��re�at�o� a�d t�rom�os�s, a�d amel�o�
rat�o� of ox�dat�ve stress. Therefore, �e�efi��al effe�ts of stat��s 
are o�served �ot o�ly �� pat�e�ts ��t� �yperl�p�dem�a ��t also 
�� t�ose ��t� �ormal ��olesterol level. �� add�t�o� to �s��em�� 
�eart d�sease, stat��s may red��e t�e r�sk of �s��em�� stroke, left 
ve�tr���lar �ypertrop�y, arr�yt�m�as, Alz�e�mer’s d�sease, type 
2 d�a�etes mell�t�s, slo� t�e pro�ress�o� of ��ro��� �ep�ropa�
t��es, r�e�mato�d art�r�t�s a�d m�lt�ple s�leros�s, a�d ���rease 
�o�e m��eral de�s�ty (3�7).
 Stat��s ������t t�e rate�l�m�t��� step of t�e mevalo�ate �as�
�ade (F��. 1); t�e releva�t prod��ts of ����� �e��� �ot o�ly 
��olesterol ��t also ma�y ot�er �ompo��ds referred to as �o��
stero�d �sopre�o�ds. Amo�� t�em, �oe�zyme Q (���q���o�e) 
�s a� ele�tro� �arr�er �� m�to��o�dr�al resp�ratory ��a�� a�d 
a� �mporta�t e�do�e�o�s l�p�d�sol��le a�t�ox�da�t prese�t 
�� plasma mem�ra�es a�d plasma l�poprote��s. Far�esylpyro�
p�osp�ate (FPP) a�d �era�yl�era�ylpyrop�osp�ate (��PP) 
are posttra�slat�o�ally atta��ed to var�o�s small �TP����d��� 
prote��s s��� as Ras, R�o a�d Ra� ����� re��late �ell �ro�t�, 
Figure 1. Mevalonate cascade and mechanism of action of statins. Broken arrows abbreviate multiple step reactions.
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prol�ferat�o� a�d s�rv�val, ��tra�ell�lar ves���lar tra�sport, et�. 
Dol���ol �s a� esse�t�al �arr�er of �ar�o�ydrate mo�et�es �sed 
for prote�� ���ly�osylat�o� – t�e pro�ess �r���al for tra�sport 
of mem�ra�e�tar�eted prote��s a�d t�e�r ��olo���al a�t�v�t�es. 
Deplet�o� of t�ese �o�stero�d �sopre�o�ds �s respo�s��le for 
��olesterol���depe�de�t ple�otrop�� a�t�v�t�es of stat��s ��t also 
�o�tr���tes to t�e�r adverse effe�ts. Alt�o��� stat��s are �s�ally 
safe a�d �ell�tolerated, �mporta�t �ompl��at�o�s s��� as myopa�
t�y, �epatotox���ty, poly�e�ropat�y, a�d �astro��test��al d�st�r�
�a��es develop �� a small s��set of pat�e�ts.
 Lo�er��� plasma ��olesterol res�lts ma��ly from t�e �������
t�o� of �epat�� �M��CoA red��tase, ��ereas ��olesterol���de�
pe�de�t effe�ts may �e exerted �� every �ell type. Most ��rre�tly 
�sed stat��s ex�ept pravastat�� a�d ros�vastat�� are l�pop��l��, 
eas�ly permeate plasma mem�ra�es, a�d affe�t �ot� �epat�� a�d 
extra�epat�� �M��CoA red��tase. Pravastat�� a�d ros�vasta�
t�� are �ydrop��l�� a�d eas�ly pe�etrate o�ly ��to �epato�ytes 
t�ro��� plasma mem�ra�e or�a��� a��o� tra�sporter. Th�s, 
alt�o��� t�ey may �e as effe�t�ve as ot�er stat��s �� red����� 
plasma ��olesterol, t�ey m��� less effe�t�vely ������t mevalo�ate 
�as�ade �� extra�epat�� �ells.
 S�mvastat�� a�d lovastat�� are �sed as ��a�t�ve la�to�es ����� 
are in vivo e�zymat��ally �ydrolyzed to a�t�ve free a��ds (8). 
S�mvastat��, lovastat�� a�d atorvastat�� are meta�ol�zed �y �y�
to��rome P450 CY3A4 �soform a�d t�e�r meta�ol�sm may �e 
�mpa�red �y ot�er s��strates or ������tors of t��s e�zyme (9). 
Fl�vastat�� �s �ot meta�ol�zed �y CYP3A4 ��t �y CYP2C9. 
Pravastat�� a�d ros�vastat�� are t�e o�ly stat��s ����� are �� 
s��sta�t�al amo��ts ex�reted �� �r��e �� t�e ����a��ed form, 
alt�o��� a�o�t 10% of adm���stered ros�vastat�� �s also meta��
ol�zed �y CYP2C9 (10). These �ydrop��l�� stat��s are meta�o�
l�zed to a m��� lo�er de�ree t�a� ot�er �M��CoA red��tase 
������tors a�d t��s are less pro�e to ��tera�t ��t� ot�er CYP 
s��strates.
 Stat��s are ��rre�tly �sed �y 25�30 m�ll�o�s people �orld�
��de, mostly �y t�ose ��t� re�o���zed �ard�ovas��lar d�seases 
or ��t� ���reased r�sk of t�ese pat�olo��es. �� t�e ot�er �a�d, 
over�e���t a�d o�es�ty are �mporta�t r�sk fa�tors of �yperl�p��
dem�a, at�eros�leros�s, arter�al �yperte�s�o� a�d �eart fa�l�re. 
�� add�t�o�, �mpa�red �l��ose tolera��e or type 2 d�a�etes are 
freq�e�tly o�served �� over�e���t/o�ese s���e�ts a�d are ofte� 
a��ompa��ed �y dysl�p�dem�a. Th�s, t�e lar�e fra�t�o� of stat���
treated pat�e�ts �ave ex�ess of ad�pose t�ss�e a�d t�erefore, t�e 
effe�t of stat��s o� t��s t�ss�e �s �l����ally s����fi�a�t. �o�ever, 
�� �ompar�so� to a �reat �ody of data a�o�t stat��s a���m�lated 
over t�e last t�o de�ades, relat�vely l�ttle �s k�o�� a�o�t t�e�r ef�
fe�ts o� ad�pose t�ss�e. �� t��s art��le � rev�e� t�e ��rre�t k�o�l�
ed�e �� t��s field.
Effect of statins on body weight and energy balance
Most st�d�es �ave s�o�� �o effe�t of stat��s adm���stered at 
p�arma�olo���al doses o� food ��take, e�er�y expe�d�t�re, 
�ody �e���t a�d ad�pos�ty �� a��mals fed sta�dard d�et (11,12). 
�� add�t�o�, �o �ross effe�t of stat��s o� �ody �e���t or ad�pos�
�ty �as o�served �� stat���treated pat�e�ts. Re�e�tly, Arak� et al 
(13) �ave demo�strated t�at pravastat�� (100 m�/k� for 28 days) 
de�reased �e���t �a�� a�d v�s�eral fat a���m�lat�o� �� m��e 
fed ������alor�e d�et. Moreover, pravastat�� ���reased oxy�e� 
�o�s�mpt�o� a�d red��ed resp�ratory q�ot�e�t. These res�lts 
s���est t�at stat��s may preve�t t�e developme�t of o�es�ty �y 
���reas��� e�er�y expe�d�t�re. �o�ever, t�e dose of pravastat�� 
�sed �� t��s st�dy �as ����er t�a� �� most exper�me�tal st�d�es. 
�� add�t�o�, t�ese res�lts �eed to �e �o�firmed for ot�er stat��s 
a�d ot�er models of o�es�ty.
Effect of statins on adipocyte differentiation  
and survival
D�ffere�t�at�o� of pread�po�ytes to ad�po�ytes �s esse�t�al for 
ad�pose t�ss�e �ro�t� a�d also �s a �r���al pro�ess �� t�e de�
velopme�t of o�es�ty. W�e� t�e amo��t of tr��ly�er�des a����
m�lated per ea�� ex�st��� ad�po�yte rea��es t�e t�res�old level, 
�ovel pread�po�ytes are re�r��ted to d�ffere�t�ate ��to mat�re 
fat �ells a�d a���m�late t�e s�rpl�s of ava�la�le e�er�y. From 
t��s mome�t, o�es�ty �e�omes “�yperplast��” (more fat �ells) 
��stead of �ypertrop��� (more tr��ly�er�des/�ell ��t ����a��ed 
�ell ��m�er). �yperplast�� o�es�ty �s more res�sta��e to treat�
me�t s���e ���rease �� t�e amo��t of ad�po�ytes �s �rrevers��le. 
Pread�po�yte d�ffere�t�at�o� �s ���t�ated �y t�o tra�s�r�pt�o� 
fa�tors: perox�some prol�ferator�a�t�vated re�eptor�γ (PPAR�γ) 
a�d CCAT e��a��er����d��� prote���α (C/�BP�α), ����� re���
late t�e express�o� of ad�po�yte�spe��fi� �e�es s��� as e�zymes 
��volved �� tr��ly�er�de stora�e, lept��, ad�po�e�t�� et�. �� t�e 
ot�er �a�d, pread�po�yte fa�tor�1 (Pref�1) �s a ma�or ������tor of 
pread�po�yte d�ffere�t�at�o�.
 Several st�d�es �ave demo�strated t�at var�o�s stat��s ���
����t pread�po�yte d�ffere�t�at�o� in vitro. ��s��o et al (14) first 
demo�strated t�at lovastat�� a�d s�mvastat�� ������ted d�ffere��
t�at�o� of ��lt�red m�r��e 3T3�L1 pread�po�ytes as ev�de��ed 
�y red��ed ��m�er of l�p�d droplets a�d t�e amo��t of tr���
ly�er�des �� stat���treated �ells. Th�s effe�t �as amel�orated �y 
mevalo�ate, far�esyl� or �era�yl�era�ylpyrop�osp�ate ��t �ot 
�y sq�ale�e or ��olesterol. These res�lts ��d��ate t�at t�e effe�t 
of stat��s �s med�ated �y deplet�o� of �o��stero�d �sopre�o�ds. 
These o�servat�o�s �ere later �o�firmed �y ot�er a�t�ors (15) 
a�d also �� ot�er �ell l��es ���l�d��� �o�e marro� stromal �ells 
(16�18).
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 Red yeast r��e �as �ee� �sed as a �at�ral food �olora�t a�d 
preservat�ve, a�d as a trad�t�o�al med����e for �mprov��� food 
d��est�o� a�d �lood ��r��lat�o� �� or�e�tal �o��tr�es. ��terest�
���ly, red yeast r��e extra�t, ����� �o�ta��s lovastat��, dose�de�
pe�de�tly de�reased d�ffere�t�at�o� of 3T3�L1 �ells as ev�de��ed 
�y red��ed a�t�v�ty of a key e�zyme of tr��ly�er�de sy�t�es�s, 
�ly�erol 3�p�osp�ate de�ydro�e�ase (�PD�), de�reased tr���
ly�er�de �o�te�t, a�d 30�50% fall �� t�e express�o� of PPAR�γ, 
C/�BP�α, ad�po�yte fatty a��d����d��� prote���2 (aP2) a�d lep�
t�� (19).
 ����olso� et al (20) o�served t�at p�tavastat�� red��ed 
PPAR�γ a�d ���reased Pref�1 express�o� �� 3T3�L1 �ells ���le 
�av��� �o effe�t o� PPAR�γ D�A����d��� a�t�v�ty. S�rpr�s�
���ly, p�tavastat�� ���reased C/�BP�α express�o�. �o�ever, re�
d��t�o� of PPAR�γ a�d st�m�lat�o� of Pref�1 �ere s�ffi��e�t to 
������t �ell d�ffere�t�at�o�, as ev�de��ed �y red��ed ��m�er of 
l�p�d droplets, tr��ly�er�de �o�te�t, fatty a��d ���d��� prote��s 
(CD36 a�d aP2), sol�te �arr�er 2A4 (SLC2A4)/�l��ose tra�s�
porter �LUT4 express�o� a�d ad�ps�� se�ret�o�. ��terest���ly, 
alt�o��� t�ese effe�ts of p�tavastat�� �ere reprod��ed �y ros�v�
astat�� a�d s�mvastat��, t�ey �ere �ot preve�ted �y mevalo�ate 
or ��olesterol, s���est��� t�at a�t��ad�po�e��� effe�t of stat��s 
�s ��depe�de�t of t�e ������t�o� of �M��CoA red��tase. �� 
�mmortal�zed m�r��e ep�dyd�mal pread�po�ytes, atorvastat�� 
red��ed l�p�d a���m�lat�o�, C/�BP�α express�o� a�d �mpa�red 
��s�l���st�m�lated l�po�e�es�s (21).
 �� �o�trast, Fa�as et al (22) �ave s�o�� t�at treatme�t of 3T3�
L1 �ells ��t� e�t�er s�mvastat�� or mevastat�� ���reased PPAR�γ 
express�o�. Th�s effe�t �as med�ated �y stat�����d��ed a�t�va�
t�o� of sterol respo�se eleme�t����d��� prote���1 (SR�BP�1) 
– tra�s�r�pt�o� fa�tor a�t�vated �y ��olesterol deplet�o�. The 
d�ffere��e �et�ee� res�lts of t��s st�dy a�d st�d�es me�t�o�ed 
a�ove �s most l�kely asso��ated ��t� ��lt�re �o�d�t�o�s – a�t�ors 
�sed ��olesterol�free med��m ����� favored stat�����d��ed 
��olesterol deplet�o�. �� ��olesterol�replete med�a stat��s are 
��l�kely to red��e ��tra�ell�lar ��olesterol s��sta�t�ally ��t re�
d��e �o��stero�d �sopre�o�ds. �� add�t�o�, lo�er stat�� �o��e��
trat�o� (0.5 μM vs. 1�10 μM �� ot�er st�d�es) �as �sed (22).
 Re�e�tly, Madse� et al (23) �ave demo�strated t�at l�pop��l�� 
s�mvastat�� ��d��es apoptos�s of d�ffere�t�at��� 3T3�L1 pread��
po�ytes ��t �ot of d�ffere�t�ated �ells. The effe�t of s�mvastat�� 
�as preve�ted �y sy�t�et�� l�ver X re�eptor (LXR) a�o��sts, 
T0901317 a�d �W3965. LXR are l��a�d�a�t�vated tra�s�r�p�
t�o� fa�tors ����� �eterod�mer�ze ��t� t�e ret��o�d X re�ep�
tor a�d, �po� l��a�d ���d���, re��late t�e express�o� of tar�et 
�e�es. LXR are a�t�vated �y e�do�e�o�s e�zymat��ally�formed 
oxy�e�ated ��olesterol der�vat�ves (oxysterols) s��� as 24(S)�, 
25� or 27��ydroxy��olesterol as �ell as �y 24(S),25�epoxy��o�
lesterol, t�e prod��t of t�e “s���t pat��ay” of t�e mevalo�ate 
�as�ade (F��. 1). A�t�vated LXR st�m�late t�e express�o� of 
�e�es ��volved �� reverse ��olesterol tra�sport, �ts �o�vers�o� to 
��le a��ds a�d ��l�ary ex�ret�o�. �� add�t�o�, LXR ������t ��test��
�al ��olesterol a�sorpt�o� a�d ��olesterol sy�t�es�s. �� add�t�o�, 
LXR re��late ot�er pro�esses s��� as �mm���ty, ��flammat�o�, 
�ervo�s a�d reprod��t�ve system f���t�o�s. Several st�d�es �ave 
demo�strated t�at stat��s de�rease oxysterol �o��e�trat�o�s; es�
pe��ally t�e level of 24(S),25�epoxy��olesterol, a�d de�rease t�e 
express�o� of LXR tar�et �e�es (24, 25). Madse� et al. �ave dem�
o�strated t�at proapoptot�� effe�t of s�mvastat�� �as �ot asso���
ated ��t� t�e red��t�o� of e�t�er PPAR�γ or SR�BP express�o� 
or ��t� t�e ������t�o� of ��s�l���l�ke �ro�t� fa�tor�1 (��F�1)����
d��ed a�t�vat�o� of pros�rv�val prote�� k��ase B (PKB)/Akt. �� 
�o�trast, stat�����d��ed �ell deat� �as a��ravated �y LXRα a�d 
LXRβ �e�e k�o�ko�ts a�d �as a�ol�s�ed �y for�ed express�o� 
of �o�st�t�t�vely a�t�ve LXRα (23). Ma�ser et al (21) �ave dem�
o�strated t�at atorvastat�� ��d��es apoptos�s of d�ffere�t�at��� 
m�r��e ep�dyd�mal pread�po�ytes ��t �ot of mat�re ad�po�ytes. 
Th�s effe�t res�lted from t�e ������t�o� of PKB/Akt p�osp�or�
ylat�o�.
Role of adipose tissue in the effect of statins on plasma 
lipoproteins
�t �as �ee� re�o���zed for a lo�� t�me t�at plasma ��olesterol 
�o��e�trat�o� �s proport�o�al to �ody �e���t, ����� s���ests 
t�e l��k �et�ee� ad�pose t�ss�e a�d ��olesterol meta�ol�sm. ���
deed, ad�pose t�ss�e �o�ta��s more ��olesterol t�a� l�ver, m�s�le 
or k�d�ey ��e� expressed o� a per m� prote�� �as�s, a�d more 
t�a� all ot�er or�a�s ��e� expressed o� a per � of t�ss�e �a�
s�s. Ad�pose t�ss�e ��olesterol pool �o�st�t�tes a�o�t 25% of t�e 
��ole��ody ��olesterol �o�te�t a�d may ���rease �p to 50% �� 
o�ese s���e�ts. �o�ever, ��olesterol t�r�over �� ad�pose t�ss�e 
�s relat�vely slo�. The a�t�v�ty of ��olesterol ��osy�t�es�s pat��
�ay �� ad�po�ytes �s lo�er t�a� �� ot�er t�ss�es a�d most of 
��olesterol �s prov�ded �y plasma l�poprote��s. Th�s, alt�o��� 
l�pop��l�� stat��s are expe�ted to a���m�late �� fat �ells �� s���
sta�t�al amo��ts, �t �s ��l�kely t�at ad�pose t�ss�e �o�tr���tes 
s����fi�a�tly to stat�����d��ed ������t�o� of ��olesterol sy�t�e�
s�s (26). D�e to lo� ��olesterol sy�t�es�s ��t ���� ��olesterol 
dema�d, espe��ally for a ���ld��p of plasma mem�ra�e �� rap�
�dly �ro���� ad�po�yte d�r��� tr��ly�er�de a���m�lat�o�, fat 
�ells take��p ��olesterol �ot o�ly from LDL ��t also from �DL 
t�ro��� at least t�o me��a��sms (27): (i) s�ave��er re�eptor 
type B1 (SR�B1)�depe�de�t (2/3 of ��olesterol �ptake), a�d 
(ii) SR�B1 ��depe�de�t, ����� req��res ��olesterol ester tra�s�
fer prote�� (C�TP), apol�poprote�� � a�d LDL re�eptor�related 
prote�� (LRP). Z�ao et al (28) �ave demo�strated t�at �������o�
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lesterol d�et de�reases SR�B1 express�o� �� ra���t s����ta�eo�s 
ad�pose t�ss�e, ��ereas atorvastat�� adm���stered at 2.5 m�/k�/
day for 6 �eeks reverses t��s effe�t. �o�ever, t�e �mpl��at�o�s of 
t��s effe�t of atorvastat�� for ��olesterol �ala��e of ad�po�ytes 
�s ���lear.
 �t �s �ell k�o�� t�at stat��s red��e �ot o�ly plasma ��oles�
terol ��t also tr��ly�er�de �o��e�trat�o�. The me��a��sm of t�e 
latter effe�t ���l�des ������t�o� of �epat�� VLDL format�o� ��t 
also e��a��eme�t of t�e�r �leara��e. Apart from skeletal m�s�
�les, ad�pose t�ss�e �s t�e most �mporta�t s�te of l�poprote�� l��
pase (LPL)�dr�ve� VLDL meta�ol�sm. The effe�t of stat��s o� 
LPL �� ad�pose t�ss�e �s �o�trovers�al. �� v�tro, pravastat��, s�m�
vastat��, atorvastat�� a�d p�tavastat�� ���reased LPL express�o� 
a�d a�t�v�ty �� 3T3�L1 ad�po�ytes (29,30). �� �o�trast, �� v�vo 
st�d�es are �ot so ��am����o�s. For ��sta��e, atorvastat�� a�d 
pravastat�� ���reased LPL a�t�v�ty �� pat�e�ts ��t� type 2 d�a�e�
tes a�d �yper��olesterolem�a (31, 32) a�d s�mvastat�� (��t �ot 
atorvastat��) �ad a s�m�lar effe�t �� ��olesterol�fed ra���ts (33). 
S�mvastat�� adm���stered at a very ���� dose (120 m�/k�) for 4 
days ���reased LPL a�t�v�ty �� ad�pose t�ss�e of �ormal rats. �� 
add�t�o�, s�mvastat�� red��ed apol�poprote�� C���� (t�e LPL ���
����tor) level (34). �� �o�trast, lovastat�� (4 m�/k�/day) ���e�ted 
s����ta�eo�sly for 13 days �ad �o effe�t o� LPL express�o� �� 
lept�� re�eptor defi��e�t Z��ker fa/fa rats (35). S�m�larly, atorv�
astat�� ��ve� orally for 2 �eeks at e�t�er 5 or 30 m�/k�/day d�d 
�ot ��a��e mR�ALPL level �� ad�pose t�ss�e of fr��tose�fed rats, 
a model of �ypertr��ly�er�dem�a (36). �t s�o�ld �e �oted t�at 
stat��s red��ed plasma tr��ly�er�des �� �ot� t�ese st�d�es, ����� 
��d��ates t�at st�m�lat�o� of ad�pose t�ss�e LPL �s �ot ��d�spe��
sa�le for tr��ly�er�de�lo�er��� effe�t of t�ese dr��s.
 Some st�d�es s���est t�at stat��s m���t affe�t t�e �ala��e �e�
t�ee� tr��ly�er�de sy�t�es�s a�d l�polys�s �� ad�pose t�ss�e. For 
example, atorvastat�� red��ed t�e express�o� of a�ylat�o��st�m�
�lat��� prote�� (ASP) a�d e��a��ed t�e express�o� of �ormo�e�
se�s�t�ve l�pase (�SL) �� ad�pose t�ss�e of fr��tose�fed rats (36).
Role of adipose tissue in effect of statins on glucose 
utilization and insulin sensitivity
The effe�t of stat��s o� �l��ose meta�ol�sm a�d ��s�l�� se�s��
t�v�ty �s �o�trovers�al. �ydrop��l�� pravastat�� �as �ee� demo��
strated to red��e t�e ����de��e of �e��o�set d�a�etes �y 30% 
(37). �o�ever, several tr�als �ave demo�strated �orse���� of 
�l��ose meta�ol�sm �y s�mvastat��, atorvastat�� a�d ros�v�
astat�� �� pat�e�ts ��t� pre�ex�st��� d�a�etes (38,39), as �ell 
as ���rease �� t�e rate of o�set of �e� d�a�etes �� �o��d�a�et�
�� pat�e�ts treated ��t� t�ese dr��s (40�44). Taka�o et al (45, 
46) �ave demo�strated t�at atorvastat��, ��t �ot pravastat�� or 
p�tavastat��, ���reases plasma �l��ose a�d �ly�ated �emo�lo��� 
��A1� �o��e�trat�o�s �� pat�e�ts ��t� type 2 d�a�etes. Atorvas�
tat�� �orse�ed �l��ose meta�ol�sm �� rats ��t� streptozoto����
��d��ed d�a�etes (47) a�d �� o�ese, ��s�l�� res�sta�t a�d moder�
ately �yper�ly�em�� �SY m��e (39).
 Ad�pose t�ss�e �s o�e of t�e ma�or s�tes of �l��ose d�sposal 
a�d a key tar�et for ��s�l��. Th�s, ad�pose t�ss�e may �e t�e 
ma�� tar�et for ��favora�le effe�t of stat��s o� �l��ose meta�o�
l�sm. There are at least t�ree me��a��sms t�ro��� ����� stat��s 
m���t �mpa�r ��s�l�� se�s�t�v�ty of ad�po�ytes. F�rst, as des�r��ed 
a�ove, stat��s ������t ad�po�yte d�ffere�t�at�o�. D�ffere�t�ated 
ad�po�ytes are m��� more ��s�l���se�s�t�ve t�a� �o��mat�re 
fat �ells. Th�azol�d��ed�o�e der�vat�ves (PPAR�γ a�o��sts), �sed 
�� t�e treatme�t of type 2 d�a�etes, �mprove ��s�l�� se�s�t�v�ty 
part�ally �y st�m�lat��� ad�po�yte d�ffere�t�at�o�. �akata et al 
(39) �ave demo�strated t�at atorvastat�� red��es t�e express�o� 
of SLC2A4/�LUT4, �l��ose tra�sporter ��volved �� ��s�l���
st�m�lated �l��ose �ptake, �� 3T3�L1 ad�po�ytes, ����� res�lts 
from �mpa�red �ell d�ffere�t�at�o� as ev�de��ed �y t�e s�m�lta�
�eo�s red��t�o� of PPAR�γ a�d C/�BP�α express�o�. S�mvasta�
t�� �as 1000 t�mes less pote�t a�d pravastat�� �ad �o effe�t at 
all. Alt�o��� s�mvastat�� �s l�pop��l��, �t �s �sed as a� ��a�t�ve 
pro�dr�� (s�mvastat�� la�to�e) ����� m�st �e e�zymat��ally �y�
drolyzed to free a��d in vivo; t��s �o�ld expla�� �ts lo� pote��y �� 
��lt�red ad�po�ytes. �� add�t�o�, atorvastat�� markedly red��ed 
t�e express�o� of ��s�l�� re�eptor β�s�����t (�R�β). These effe�ts 
�ere a��ompa��ed �y red��ed ��s�l�����d��ed PKB/Akt p�os�
p�orylat�o� a�d �l��ose �ptake. ��terest���ly, atorvastat�� �ad 
�o effe�t o� SLC2A4/�LUT4 express�o� �� ��lt�red skeletal my�
o�ytes ��d��at��� t�at �ts effe�t �s spe��fi� for ad�po�ytes (39). �� 
f�lly d�ffere�t�ated 3T3�L1 ad�po�ytes t�e effe�t of atorvastat�� 
o� SLC2A4 express�o� a�d ��s�l���st�m�lated �l��ose �ptake 
�as st�ll o�served ��t �as m��� less pro�o���ed t�a� �� d�f�
fere�t�at��� �ells. �o�ever, �� �o�trast to �mmat�re ad�po�ytes, 
atorvastat�� ���reased t�e express�o� of �R�β a�d ��s�l�� re�ep�
tor s��strate�1 (�RS�1) �� f�lly d�ffere�t�ated ad�po�ytes (39).
 Se�o�d, ��s�l�� st�m�lates prote�� far�esyl� a�d �era�yl�era�
�yltra�sferases (48, 49), a�d �sopre�ylated prote��s are ��volved 
�� some aspe�ts of ��s�l�� s���al���. For example, Ra�4 prote�� �s 
��volved �� ��tra�ell�lar ves���lar tra�sport of SLC2A4/�LUT4 
from ��a�t�ve ��tra�ell�lar pool to t�e plasma mem�ra�e; t�e key 
pro�ess �� ��s�l�����d��ed �l��ose �ptake. Taka��r� et al (50) 
�ave re�e�tly demo�strated t�at atorvastat�� ��t �ot pravasta�
t�� de�reases ��s�l�����d��ed 2�deoxy�l��ose �ptake �y mat�re 
3T3�L1 ad�po�ytes �y atte��at��� ��s�l�����d��ed tra�slo�a�
t�o� of SLC2A4/�LUT4 to t�e plasma mem�ra�e. Atorvastat�� 
�ad �o effe�t o� ��s�l�����d��ed tyros��e p�osp�orylat�o� of 
t�e �R�β as �ell as o� a�sol�te level of SLC2A4/�LUT4 mR�A 
a�d prote��, s���est��� t�at �mpa�red tra�slo�at�o� of �l��ose 
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tra�sporter plays a ma�or role �� �mpa�r��� ��s�l�� se�s�t�v�ty. 
The effe�t of atorvastat�� �as a��ompa��ed �y t�e ���rease �� t�e 
amo��t of Ra�4 �� t�e �ytosol�� fra�t�o� a�d de�rease �� �ts �o��
te�t �� t�e mem�ra�e fra�t�o�. S���e tra�slo�at�o� of Ra�4 to 
t�e mem�ra�e fra�t�o� �s depe�de�t o� �ts �sopre�ylat�o�, t�ese 
data s���est t�at atorvastat�� �mpa�rs SLC2A4/�LUT4 tra�slo�
�at�o� se�o�dar�ly to atte��at��� �sopre�ylat�o� of Ra�4.
 F��ally, var�o�s stat��s �mpa�red �ly�osylat�o� of ��s�l�� re�
�eptor �� 3T3�L1 ad�po�ytes, ����� res�lted �� �mpa�red tra�s�
lo�at�o� of t��s re�eptor to t�e plasma mem�ra�e a�d a���m��
lat�o� of ���ly�osylated re�eptors �� e�doplasm�� ret���l�m 
(51). Th�s effe�t, as �ell as �mpa�rme�t of ��s�l�����d��ed �l��
�ose �ptake, �as reprod��ed �y sele�t�ve ������tors of prote�� 
�ly�osylat�o� ��t �ot �y far�esyltra�sferase ������tors. Th�s, 
stat�����d��ed dol���ol defi��e��y may �mpa�r ��s�l�� s���al��� 
�y ��terfer��� ��t� ��s�l�� re�eptor �ly�osylat�o�.
Statins and adipose tissue inflammation
Re�e�t st�d�es ��d��ate t�at o�es�ty a�d t�e meta�ol�� sy��
drome are asso��ated ��t� ��ro��� lo���rade ��flammat�o� 
of t�e ad�pose t�ss�e a��ompa��ed �y a���m�lat�o� of ma��
rop�a�es a�d mast �ells ����� express pro��flammatory �y�
tok��es s��� as t�mor �e�ros�s fa�tor�α (T�F�α), mo�o�yte 
��emoattra�ta�t prote���1 (MCP�1) or ��terle�k���6 (�L�6); 
some of t�em �e��� sy�t�es�zed also �y ad�po�ytes t�emselves. 
Ad�pose t�ss�e ��flammat�o� �o�tr���tes to ��s�l�� res�sta��e 
a�d a��ormal�t�es of �l��ose meta�ol�sm asso��ated ��t� o�es�
�ty. Ad�pose t�ss�e ��flammat�o� �s dr�ve�, at least �� part, �y 
a�t�vat�o� of l�popolysa���ar�de (LPS) re�eptor, Toll�l�ke re�
�eptor�4 (TLR�4), �y sat�rated fatty a��ds, a�d �y �ypox�a (see 
Tray��r� et al �� t��s vol�me of Adipobiology). A�e et al (52) 
�ave demo�strated t�at pravastat�� or p�tavastat�� adm���s�
tered to lept���defi��e�t ob/ob m��e red��ed t�e express�o� of 
MCP�1, T�F�α a�d �L�6 �e�es �� ep�dyd�mal a�d s����ta�e�
o�s ad�pose t�ss�e. Stat��s �ad �o effe�t o� �ody �e���t as �ell 
as o� t�e amo��t of ma�rop�a�es �� ad�pose t�ss�e. In vitro 
st�d�es revealed t�at �o�d�t�o�ed med��m of ��lt�red LPS�
treated ma�rop�a�es st�m�lated ��flammatory respo�se of 
ad�po�ytes ��t t��s effe�t �as s�ppressed �f ma�rop�a�es (��t 
�ot ad�po�ytes) �ee pretreated ��t� stat��s. ��deed, pravasta�
t�� a�d p�tavastat�� red��ed t�e express�o� of MCP�1, T�F�α, 
�L�6 a�d ��d����le ��tr�� ox�de sy�t�ase (���S) �� LPS�treated 
ma�rop�a�es. The TLR�4 re�eptor tr���ers t�o s���al��� pat��
�ays: (i) re�r��tme�t of Toll/�L�1 re�eptor (T�R)�doma����o��
ta����� adaptor prote�� MyD88, ����� t�e� a�t�vates ���lear 
fa�tor�κB (�F�κB) a�d ��J�� ��term��al k��ase (J�K), a�d 
(ii) re�r��tme�t of T�R doma����o�ta����� adaptor ��d����� 
�F��γ (TR�F), lead��� to t�e a�t�vat�o� of tra�s�r�pt�o� fa�tor 
�RF3 ����� t�e� a�t�vates �F��γ promoter a�d st�m�lates �ts 
sy�t�es�s. Stat��s ������ted p�osp�orylat�o� of �RF3, sy�t�es�s 
of �F��γ, a�d p�osp�orylat�o� of �ts s���al��� tar�et, STAT1 
prote��. �� �o�trast, pravastat�� or p�tavastat�� �ad �o effe�t 
o� MyD88�depe�de�t s���al���. Colle�t�vely, t�ese data ��d��
�ate t�at stat��s ������t MyD88���depe�de�t TLR�4 s���al��� 
�� ad�pose t�ss�e ma�rop�a�es lead��� to t�e atte��at�o� of 
�F��γ format�o� a�d red��t�o� of pro��flammatory respo�se 
of ad�po�ytes as �ell as ma�rop�a�es t�emselves (52). Treat�
me�t ��t� atorvastat�� red��ed prod��t�o� of C�rea�t�ve pro�
te�� (CRP) (53), �L�6 (54), a�d T�F�α (55) �y ad�po�ytes of 
��olesterol�fed ra���ts. In vitro, atorvastat�� (54) a�d �er�vas�
tat�� (56) de�reased �L�6 express�o� �y ��lt�red ra���t a�d ���
ma� ad�po�ytes. F��ally, s�mvastat�� a�d pravastat�� de�reased 
�ytok��e�st�m�lated express�o� of ���S �� 3T3�L1 ad�po�ytes 
(57). Red��t�o� of ad�pose t�ss�e ��flammat�o� may �o�tr���te 
to �e�efi��al effe�ts of stat��s o� ��s�l�� se�s�t�v�ty a�d also to 
t�e ������t�o� of at�ero�e�es�s.
Statins and adipokines
Ad�pok��es play a� �mporta�t role �� ad�pose t�ss�e p�ys�olo�y 
a�d �� o�es�ty�asso��ated �ompl��at�o�s (58). �ere��, � fo��s o� 
effe�t of stat��s o� most exte�s�vely st�d�ed ad�pok��es: lept��, 
ad�po�e�t��, res�st�� a�d v�sfat��.
Leptin
Z�ao et al (59) �ave demo�strated t�at �������olesterol d�et 
���reases plasma lept�� �o��e�trat�o� �� t�e ra���t more t�a� 
2�fold ��t�o�t ��a����� �ody �e���t or ad�pos�ty. Co��om��
ta�t treatme�t ��t� atorvastat�� red��ed ser�m lept�� a�d lep�
t�� mR�A �� s����ta�eo�s ad�pose t�ss�e s�m�lta�eo�sly ��t� 
de�reas��� LDL���olesterol ��t �ad �o effe�t o� �ody �e���t. 
These data s���est t�at stat��s may de�rease lept�� level. The 
me��a��sm of t��s effe�t �s ���lear ��t may ���l�de red��t�o� 
of e�t�er ad�pose t�ss�e ��flammat�o� or ox�dat�ve stress �e�a�se 
�ot� t�ese �o�d�t�o�s st�m�late lept�� prod��t�o�.
 �ffe�t of stat��s o� plasma lept�� �o��e�trat�o� �� ��ma�s 
�as addressed �� 9 �l����al st�d�es (Ta�le 1). �� most of t�em, 
stat��s d�d �ot ��a��e lept�� level s����fi�a�tly. ��e st�dy dem�
o�strated de�rease a�d o�e ���rease �� lept��. Ko� et al (63) 
�ompared t�e effe�t of s�mvastat�� a�d pravastat�� �� a �ross�
over st�dy �� t�e same �ro�p of �yper��olesterolem�� pat�e�ts. 
They o�served t�at l�pop��l�� s�mvastat�� ��t �ot �ydrop��l�� 
pravastat�� ���reased ser�m lept�� �o��e�trat�o�. Alt�o��� 
t�ese data s���est t�at var�o�s stat��s may �ave d�ver�e�t effe�ts 
o� lept�� level, t�e overall a�alys�s of data prese�ted �� Ta�le 1 





Ma�ser et al (21) �ave demo�strated t�at atorvastat�� red��ed 
ad�po�e�t�� express�o� �� d�ffere�t�ated 3T3�L1 ad�po�ytes. 
�� �o�trast, pravastat�� ���reased ad�po�e�t�� se�ret�o� �� t�e 
same �ell ��lt�re, a�d �pre��lated ad�po�e�t�� �e�e express�o� 
a�d elevated �ts plasma level �� lept�� re�eptor defi��e�t db/db 
m��e as �ell as �� �����fat a�d �����s��rose fed C57BL/6J m��e 
(69). Th�s effe�t of pravastat�� �orrelated ��t� t�e �mproveme�t 
of ��s�l�� se�s�t�v�ty a�d �as �ot a��ompa��ed �y a�y ��a��es 
�� �ody �e���t. S�mvastat�� d�d �ot ��a��e e�t�er ad�po�e�t�� 
level or ��s�l�� se�s�t�v�ty. A�t�ors s���est t�at effe�t o� ad��
po�e�t�� may expla�� d�ffere�t�al ��fl�e��e of �ydrop��l�� a�d 
l�pop��l�� stat��s o� �l��ose meta�ol�sm (69).
 Alt�o��� lept�� �s t�e �est ��ara�ter�zed ad�pok��e, m��� 
more st�d�es addressed t�e effe�t of stat��s o� ad�po�e�t�� �� 
var�o�s pat�e�t �ro�ps. Amo�� t�em, ���rease, de�rease or �o 
��a��e �� ad�po�e�t�� follo���� stat�� treatme�t �as �oted �� 
20, 4 a�d 20 st�d�es, respe�t�vely (Ta�le 2). �f ��a��es �� ad��
po�e�t�� �ere o�served, t�ey �ere relat�vely small, rarely ex�
�eed��� 20�30%. The lar�est effe�t �as o�served for ros�vastat�� 
(73). A�t�ors ��o o�served ���rease �� ad�po�e�t�� �s�ally s���
�est t�at �t m���t �o�tr���te to a�t�at�ero�e��� a�d a�t�d�a�et�� 





Treatment Leptin concentration* Comments Ref.
Type 2 diabetes 32
Atorvastatin  
40 mg/day  
8 weeks
-40% Placebo-controlled study 60
Non-alcoholic steatohepatitis with 
hyperlipidemia 31
Atorvastatin  
10 mg/day  
24 months
No change No placebo group 61
Overweight with impaired glucose 
tolerance but not diabetes 30
Simvastatin  
20 mg/day  
16 weeks
No change No placebo group 62
Hypercholesterolemia 43
Simvastatin  


















Healthy non-diabetic volunteers 
without ischemic heart disease 40
Pravastatin  
40 mg/d  
12 weeks
No change Placebo-controlled study 64
Hypercholesterolemia without 










ischemic heart disease 36
Pravastatin  
10 mg/day  
16 weeks
No change




Type 2 diabetes with 
hyperlipidemia 29
Atorvastatin 10-
40 mg/day  
12 weeks






No placebo group, 







No change No placebo group 68
* Post-treatment vs. pre-treatment percent change of mean or median concentration
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Treatment Adiponectin concentration* Comments Ref.
Non-alcoholic steatohepatitis with 
hyperlipidemia 31
Atorvastatin  
10 mg/day  
24 months
+25% No placebo group 61
Hypercholesterolemia 43
Pravastatin  




Increase in insulin sensitivity 
during pravastatin treatment
63
Ischemic heart disease with  
impaired glucose tolerance 20
Pravastatin  




Increase in insulin sensitivity 
during treatment was 
correlated with increase in 
adiponectin
70
Type 2 diabetes with hyperlipidemia 64
Pitavastatin  
2 mg/day  
6 months
+25% No placebo group 71
Hyperlipidemia with mild 
hypertension 27
Pravastatin  
20 mg/day  
6 months
+10%
No placebo group  
Compared to previous 





10 mg/day  
12 weeks
+68% No placebo group 73
Primary hypercholesterolemia 34
Atorvastatin  
10 mg/day  
12 weeks
+15% No placebo group 73
Ischemic heart disease 22
Atorvastatin  
10 mg/day  
12 weeks
+39% No placebo group 74
Ischemic heart disease or diabetes 
or peripheral artery occlusive 
disease or cerebrovascular disease 








at 40 and 80 mg/day 
(+25%). Less marked 
increase in patients 
with diabetes or 
metabolic syndrome
No placebo group 75
Hyperlipidemia 72
Pitavastatin  
2 mg/day  
6 months
+24% Placebo-controlled study 76
Hypercholesterolemia without 
ischemic heart disease 36
Atorvastatin  
10 mg/day  
16 weeks
+7% No placebo group, compared to pravastatin-treated group 65
Type 2 diabetes 52
Atorvastatin  
40 mg/day  
8 weeks






Familial combined hyperlipidemia, 
non-obese patients 22
Atorvastatin  
10 mg/day  
24 weeks
+13%




Stable ischemic heart disease with 
mixed hyperlipidemia 16
Atorvastatin  
10 mg/day  
4 weeks or  
6 months
+25% Placebo-controlled study 79
Type 2 diabetes 30
Atorvastatin  
10 mg/day  
12 weeks
+32%  
(vs. treatment with 
rosiglitazone alone)
No placebo group 









Treatment Adiponectin concentration* Comments Ref.
Ischemic heart disease with 
hypercholesterolemia 115
Pravastatin  
10 or 20 mg/day  
6 months
+16% No placebo group 81
Ischemic heart disease; patients 
undergoing coronary artery bypass 




10 mg/day  
2 months before 
CABG
+42.3% in serum 





+200% (mRNA in 
visceral adipose 
tissue)
No follow-up observation, 
Percent change compared  
to group receiving no statin  
(with LDL-cholesterol < 
100 mg/dl)
82
Stable ischemic heart disease 16
Pitavastatin  
2 mg/day  
6 months
+20% No placebo group 83
Hyperlipidemia with or without 
diabetes 117
Pitavastatin  
2 mg/day  
6 months
+25% in diabetic 
patients 
No change in non-
diabetics
No placebo group 84
Hyperlipidemia with or without type 
2 diabetes 75
Pitavastatin  
2 mg/day  
3 or 6 months
Diabetic patients:
+37% (3 months) 
+64% (6 months) 
Non-diabetic 
patients: no change
No placebo group 
Similar reduction of plasma 









Decrease in insulin sensitivity 
by 7% during statin treatment
63
Nondiabetic patients with 
ischemic heart disease, carotid 




40 mg/day  
12 weeks
-12%
No placebo group 
Compared with group treated 
with pioglitazone
86
Ischemic heart disease - stable 
angina and normal lipid profile, 
patients scheduled for coronary 




10 mg/day  
6 months
-20% Placebo-controlled study 87
Hypercholesterolemia 124
Simvastatin  
10-80 mg/day  
8 weeks
Dose-dependent 





10 mg/day  
8 weeks
No change Placebo-controlled study 89
Type 1 or type 2 diabetes 77
Atorvastatin  
20 mg/day  
12 weeks
No change Placebo-controlled study 90
Overweight with impaired glucose 
tolerance but not diabetes 30
Simvastatin  
20 mg/day  
16 weeks




20 mg/day  
8 weeks
Non-significant 
reduction Placebo-controlled study 91
Type 2 diabetes 53
Simvastatin  
20 mg/day  
8 weeks
Non-significant 
reduction Placebo-controlled study 92
Continued on page 10
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Treatment Adiponectin concentration* Comments Ref.
Healthy non-diabetic volunteers 
without ischemic heart disease 40
Pravastatin  
40 mg/day  
12 weeks
No change Placebo-controlled study 64
Non diabetic patients with increased 
cardiovascular risk (thickened 
carotid artery intima-media 
thickness, history of myocardial 
infarction, proved ischemic heart 
disease in coronary angiography, 
unstable angina, cervical or leg artery 
atherosclerosis, ischemic changes 
in ECG, stroke, transient ischemic 
attack, peripheral arterial occlusion)
80
Atorvastatin  
40 mg/day  
6 months
No change No placebo group 93
Overweight patients with type 2 
diabetes and mixed hyperlipidemia 13
Atorvastatin  
10 mg/day  
6 weeks
No change No placebo group 94
Type 2 diabetes with 
hypertriglyceridemia 194
Atorvastatin  
10 or 80 mg/day  
6 months
No change Placebo-controlled study 95
Hyperlipidemia 63
Simvastatin  
10 mg/day  
6 months
No change Placebo-controlled study 76
Hypercholesterolemia without 
ischemic heart disease 36
Pravastatin  
10 mg/day  
16 weeks
No change No placebo group 65
Type 2 diabetes with hyperlipidemia 29
Atorvastatin  
10-40 mg/day  
12 weeks
No change No placebo group 66
Hypercholesterolemia 32
Atorvastatin  
10 mg/day  
12 weeks
No change No placebo group 96
Type 2 diabetes with dyslipidemia 12
Atorvastatin  
10 mg/day  
8 weeks
No change No placebo group 97
Kidney transplant recipients 68
Atorvastatin  
10 mg/day  
12 weeks
No change No placebo group 98
Hypercholesterolemia 24
Fluvastatin  
80 mg/day  
12 weeks
No change No placebo group 99
Non-smoking males with obesity/
metabolic syndrome 15
Simvastatin  
80 mg/day  
6 weeks
No change following 
either therapy
No placebo group, cross-
over study with simvastatin 





10 mg/day  
2 weeks
No change of total 
and HMW form
No placebo group, compared 













No change No placebo group 68
* Post-treatment vs. pre-treatment percent change of mean or median concentration (if not otherwise stated)
HMW – high-molecular weight adiponectin, MMW – medium-molecular weight adiponectin, LMW – low-molecular weight 
adiponectin
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effe�t of stat��s. �o�ever, t��s ���rease �s relat�vely small e.�. �� 
�ompar�so� to PPAR�γ a�o��sts (2�3 fold ���rease), for ����� 
t�e ��volveme�t of ad�po�e�t�� �� ��s�l���se�s�t�z��� effe�t �as 
demo�strated. �� t�ree st�d�es t�e effe�t of var�o�s stat��s �as 
d�re�tly �ompared. Ko� et al (63) o�served t�at pravastat�� ���
�reased ���le s�mvastat�� red��ed ser�m ad�po�e�t��, ����� 
�as a��ompa��ed �y parallel ��a��es �� ��s�l�� se�s�t�v�ty. Q� 
et al (73) fo��d t�at ros�vastat�� �as m��� more effe�t�ve �� 
elevat��� ad�po�e�t�� �� �ompar�so� to atorvastat��, alt�o��� 
�ot� dr��s s�m�larly red��ed LDL���olesterol. �om�ra et al 
(76) fo��d t�at p�tavastat�� ��t �ot s�mvastat�� sl���tly elevated 
ad�po�e�t�� level, a�d A�do et al (65) o�served t�at atorvas�
tat�� ��t �ot pravastat�� ���reased ad�po�e�t�� �y 7%. �mpor�
ta�tly, o�ly total ad�po�e�t�� �as meas�red �y most a�t�ors. 
Vo� �y�atte� et al (77) fo��d t�at atorvastat�� �ad �o effe�t 
o� total ad�po�e�t�� ��t s����fi�a�tly ���reased ���� mole��lar 
�e���t (�MW) ad�po�e�t�� a�d de�reased med��m� a�d lo��
mole��lar �e���t forms. Be�a�se �MW ad�po�e�t�� �s a ma�or 
“�e�efi��al” form of t��s ad�pok��e, ���rease �� �MW/total ad��
po�e�t�� rat�o may markedly �mprove r�sk profile of t�e treated 
pat�e�ts. �� add�t�o�, re��pro�al effe�ts o� var�o�s ad�po�e�t�� 
�soforms may expla��, at least part�ally, �o�trovers�al res�lts of 
st�d�es �� ����� o�ly total ad�po�e�t�� �as meas�red. ��am� et 
al (84) �ave fo��d t�at p�tavastat�� ���reases ad�po�e�t�� level 
o�ly �� d�a�et�� ��t �ot �� �o�d�a�et�� pat�e�ts ��t� �yperl�p��
dem�a. Clearly, �asel��e profile of r�sk fa�tors as �ell as prese��e 
or a�se��e of at�eros�leros�s may affe�t t�e effe�t of stat��s o� 
ad�po�e�t��. U�fort��ately, more �omo�e�o�s pat�e�t �ro�ps 
�ere exam��ed �� most st�d�es a�d t�e effe�t �� s���e�ts ��t� 
var�o�s r�sk profiles �as �ot d�re�tly �ompared.
Resistin
S�mvastat�� ������ted C�rea�t�ve prote�����d��ed �pre��lat�o� 
of res�st�� �e�e express�o� �� ��ma� per�p�eral �lood mo�o�
�ytes (102). The effe�t of s�mvastat�� �as reversed �y mevalo�ate 
a�d �era�yl�era�ylpyrop�osp�ate ��t �ot �y far�esylpyrop�os�
p�ate. S�m�larly, atorvastat�� red��ed res�st�� �e�e express�o� �� 
m�r��e 3T3�L1 ad�po�ytes, ��lt�red ��ma� pread�po�ytes a�d 
mo�o�yte�ma�rop�a�es (103, 104).
 �� most �l����al st�d�es, �o effe�t of stat��s o� plasma res�st�� 
level �as reported (Ta�le 3). Th�s, �t seems ��l�kely t�at red���
t�o� of res�st�� �s ��volved �� �e�efi��al effe�ts of stat��s.
Table 3. Effect of statins on plasma resistin concentration in clinical studies
Patients Number  of patients Treatment
Resistin 
concentration* Comments Ref.




-40% Placebo-controlled study 60




No change Placebo-controlled study 90
Overweight patients with 






No change No placebo group 94
Hypercholesterolemia without 
ischemic heart disease 36
Atorvastatin  
10 mg/day  
16 weeks
No change No placebo group 65
Hypercholesterolemia without 
ischemic heart disease 36
Pravastatin 
10 mg/day  
16 weeks
No change No placebo group 65
Healthy men 24
Simvastatin  
10 mg/day  
2 weeks
No change
No placebo group, compared to 





10 mg/day  
12 weeks
No change No placebo group 96
Type 2 diabetes 12
Atorvastatin  
10 mg/day  
6 months





-11% No placebo group 68
* Post-treatment vs. pre-treatment percent change of mean or median concentration
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Visfatin
Alt�o��� ���t�ally �de�t�fied as a� ��s�l���se�s�t�z��� a�e�t, 
v�sfat�� �s a� am����o�s ad�pok��e s���e �t may also ��d��e e��
dot�el�al dysf���t�o� a�d promote ��flammat�o� t��s a��ravat�
��� at�ero�e�es�s. Atorvastat�� red��es v�sfat�� �e�e express�o� 
�� m�r��e d�ffere�t�ated ���te ad�po�ytes (21). U�t�l �o�, t�e ef�
fe�t of stat�� t�erapy o� ser�m v�sfat�� level �as exam��ed o�ly 
�� 3 �l����al st�d�es. Kostapa�os et al  (105) �ave demo�strated 
t�at ros�vastat�� adm���stered at 10 m�/day for 12 �eeks re�
d��es ser�m v�sfat�� �y a�o�t 10% �� pat�e�ts ��t� pr�mary �y�
perl�p�dem�a ��t�o�t �ard�ovas��lar d�seases. �� �o�trast, s�m�
vastat�� �ad �o effe�t o� v�sfat�� �o��e�trat�o� �� �o��d�a�et�� 
pat�e�ts ��t� t�e meta�ol�� sy�drome (106). S�m�larly, 12��eek 
treatme�t ��t� atorvastat�� d�d �ot mod�fy v�sfat�� level �� pa�
t�e�ts ��t� pr�mary �yperl�p�dem�a (107).
Conclusions
Stat��s �ave m�lt�ple effe�ts �� v�rt�ally all t�ss�es a�d ad��
pose t�ss�e �s �ot a� ex�ept�o�. Most of ��rre�tly �sed stat��s 
are l�pop��l�� a�d t��s expe�ted to a���m�late �� s��sta�t�al 
amo��ts �� ad�pose t�ss�e. C�rre�tly ava�la�le data ��d��ate t�at 
alt�o��� stat��s �ave �o �ross effe�t o� �ody ad�pos�ty, ad�pose 
t�ss�e may �e t�e tar�et for �ot� �e�efi��al a�d adverse effe�ts 
of t�ese dr��s. Stat��s ������t ad�po�yte d�ffere�t�at�o�, �mpa�r 
��s�l�� s���al��� �� fat �ells, ������t ad�pose t�ss�e ��flamma�
t�o�, a�d mod�late ad�pok��e sy�t�es�s a�d se�ret�o�. �o�ever, 
ma�y effe�ts of stat��s o� ad�pose t�ss�e are �o�trovers�al, es�
pe��ally t�e�r ��fl�e��e o� VLDL �leara��e a�d ad�pok��e pro�
d��t�o�. Ma�y res�lts �ere o�ta��ed �� ��lt�red ad�po�yte �ell 
l��es a�d t��s do �ot �e�essar�ly refle�t �� v�vo s�t�at�o�. More 
exper�me�tal st�d�es are �eeded to el���date �� more deta�l ef�
fe�t of stat��s o� ad�pok��es prod��t�o� a�d t�e me��a��sm of 
t�ese effe�t, s���e t�e res�lts of �l����al st�d�es are ����ly �o�tro�
vers�al. D�e to ���reas��� �sa�e of stat��s �orld��de, el���dat��� 
t�e�r effe�ts o� ad�pose t�ss�e �s �mporta�t to �mprove t�e res�lts 
of treatme�t ��t� t�ese dr��s.
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